U.S. FDA Approves Expanded Use Of Bristol-Myers Squibb???s Daklinza(Daclatasvir) For Additional Challenging-To-Treat Patients With Genotype 1 Or Genotype 3 Chronic Hepatitis C

Press/Media: Press / Media

PeriodFeb 8 2016

Media coverage

1

Media coverage

  • TitleU.S. FDA Approves Expanded Use Of Bristol-Myers Squibb???s Daklinza(Daclatasvir) For Additional Challenging-To-Treat Patients With Genotype 1 Or Genotype 3 Chronic Hepatitis C
    Media name/outletBioSpace
    CountryUnited States
    Date2/8/16
    PersonsFred Poordad